Adalvo Secures First EU Approval For Victoza Rival

After Liraglutide Nod, Company Also Expects Ozempic Approvals In 2024 And 2025

 
• By Adam Zamecnik

Adalvo has secured the first-ever approval of a Victoza rival in the EU, paving the way for future launches in the key market ahead of competitors. 

An image of a semaglutide pen
• Source: Shutterstock

More from Biosimilars

More from Products